It is reported that Weaving Technology, the provider of innovative diagnosis and treatment solutions for brain nerve health in the field of digital health, announced the completion of its first round of financing, with a financing amount of about 10 million yuan according to the disclosure, and the investor is Noyu Capital.
Founded in Shanghai in March 2020, Ogibito Technology focuses on promoting the innovation of early screening, clinical diagnosis and intervention methods in the field of brain nerve health. At present, the "eye movement" technology model it focuses on is a new "combination of software and hardware" digital solution based on the "brain-eye" neurofeedback mechanism, combined with clinical data collection, and developed through deep learning training. The technical model is expected to enter quasi-clinical phase validation no later than the second quarter of this year after a two-year technical accumulation, and the first applicable disease selected is Alzheimer's Disease (AD).
The pathogenesis of Alzheimer's disease (AD) is still unclear and there is a lack of effective treatment, but the disease has become the fifth leading cause of death in the mainland, only lower than stroke, ischemic heart disease, chronic obstructive pulmonary disease, lung cancer, with an average survival time of only 5.5 years. More than 85% of patients with the disease are moderate to severe at first presentation, so early screening, diagnosis, and intervention are particularly important for patient outcomes. According to the China Alzheimer's Disease Report 2021, as of 2019, the number of dementia patients including Alzheimer's disease (AD) in mainland China has exceeded 13 million, and the number of prodromal symptoms, including mild cognitive impairment (MCI), has exceeded the 50 million mark.
The current clinical diagnosis method of Alzheimer's disease (AD) is to use the scale tool to allow subjects to self-evaluate, and the diagnosis of the patient as a basic reference, and further combine brain imaging (RSI) and biological testing to obtain clinical diagnosis. However, in the actual diagnosis process, the scale tool will be affected by a series of subjective factors, such as the subject's education level, understanding level, and when applied to different subjects (age, gender, education level, etc.), the discussion of the best threshold and numerical consensus has not yet reached a consensus. Therefore, the industry urgently needs more objective, low-manual intervention diagnostic tools.
The "eye tracking" technology model currently promoted by Ogibu Technology can assess the cognitive state of subjects in a more objective way, and the scenes requiring manual intervention are greatly reduced throughout the evaluation process. This innovative model can significantly lower the threshold for the diagnosis of Alzheimer's disease (AD) and improve the accuracy of diagnosis to a considerable extent, so that early screening for the condition can be carried out in a more professional and low-cost manner. Through the subsequent clinical data verification, Oriote hopes to promote the further improvement of the "eye tracking" technology model to make up for the shortcomings of existing diagnostic tools, make it a new auxiliary diagnostic means, and promote the innovation of existing diagnostic standards.
Through subsequent clinical applications and technology research and development, Oriot technology plans to further apply the "eye tracking" technology model to the diagnosis of prodromal symptoms of Alzheimer's disease (AD), including subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
Mr. Ye Jianfeng, founder of Ogibito Technology, said that the core R&D team of Ogibu Technology comes from top academic institutions such as MIT, Cambridge and the Chinese Academy of Sciences, and has a high degree of professionalism in the fields of neuroscience and cognitive science. The subsequent application scenarios of the "eye movement" technology model are not limited to diagnosis, and the intervention of SCD, MCI and AD in the early and middle stages has also entered the experimental stage. It is foreseeable that this digital solution will also be a new revolution in the field of AD interventions. At the same time, the feasibility study of the model in the field of attention deficit and Hyperactivity Disorder (ADHD), Parkinson's Disease (PD), autistic Spectrum Disorder (ASD) and other areas of brain nerve disease will be carried out in the future.
Mr. Yang Zhiwen, Managing Partner of Noble Capital, said that Alzheimer's disease (AD) is not only a patient's loss of cognitive ability, but also a black-and-white chaotic way of working and resting that can cause devastating damage to the normal work and life of all family members. Unfortunately, so far the medical community has been unable to treat Alzheimer's disease, and the only feasible way is early detection and early intervention. According to long-term clinical follow-up, early intervention can delay the onset of Alzheimer's disease for 7-8 years, which may mean that most Alzheimer's disease patients around the age of 80 may mean no more onset for life. Ogibione's "eye tracking" technology model is a revolutionary breakthrough in alzheimer's (AD) early screening, and we are firmly optimistic about their future, believing that their technology can benefit tens of millions of people at risk of Alzheimer's disease (AD).
About Noble Capital
Noyu Capital is a professional investment institution focusing on medical devices and digital healthcare. The company's vision is to be the cradle of growth for excellent medical companies, which motivates us to always look for entrepreneurs who can really solve medical problems. Every member of our investment team has been a practitioner of the medical industry for more than 10 years, which determines that we will invest with an industrial mindset. We have long adhered to the concept of integrity, kindness and inclusive cooperation to treat every entrepreneur. We firmly believe that integrity can make the world simple; that perseverance in kindness will win kindness; and that the soil of inclusion can breed greatness. Entrepreneurship is a matter of nine deaths, and no yu people with rich industrial experience hope to become a good companion for entrepreneurs and accompany them to ride the wind and waves in the ups and downs.
Main investment projects: Changmugu Medical, Weiweisi Medical, Huihe Medical, Tingsheng Technology, Zhisheng Technology, Qianglian Zhichuang.
About Ogison Technology
Founded in Shanghai in March 2020, Ogison Technology focuses on the research and development and application of digital medical solutions in the field of brain nerve health. The core R&D team comes from top academic institutions such as MIT, Cambridge and the Chinese Academy of Sciences, and has a high degree of professionalism in the fields of neuroscience and cognitive science. Ogibione is committed to applying innovative technologies, such as "eye movement" technology models, for Alzheimer's Disease (AD), Attention Deficit and Hyperactivity Disorder (ADHD), Parkinson's Disease (PD), Autistic Spectrum Disorder (ASD) and many other existing diagnostic and therapeutic tools for cranial nerve diseases are insufficient, which is an innovative way to promote the revolution of relevant diagnostic and treatment standards and interventions.
![16 common sense about the body, mind and money[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)